Yes, fatty acid synthesis does occur in the liver, making it a central hub for converting excess dietary carbohydrates into stored energy. This process, known as de novo lipogenesis, is particularly active when calorie intake exceeds immediate needs, especially with high intakes of refined carbohydrates and free sugars. Whilst this metabolic pathway serves essential physiological functions—including energy storage, lipid transport, and membrane synthesis—dysregulated hepatic fatty acid production contributes to conditions such as non-alcoholic fatty liver disease (NAFLD) and cardiovascular risk. Understanding how the liver synthesises fatty acids, what influences this process, and when it becomes problematic is crucial for managing metabolic health.
Summary: Yes, fatty acid synthesis occurs extensively in the liver through de novo lipogenesis, converting excess dietary carbohydrates into fatty acids for energy storage and lipid transport.
- The liver synthesises fatty acids from acetyl-CoA via the rate-limiting enzyme acetyl-CoA carboxylase and the multi-enzyme complex fatty acid synthase.
- High carbohydrate intake, particularly refined sugars and fructose, strongly stimulates hepatic fatty acid synthesis, whilst insulin acts as the primary hormonal activator.
- Excessive hepatic lipogenesis contributes to non-alcoholic fatty liver disease (NAFLD), cardiovascular risk through VLDL production, and atherogenic dyslipidaemia.
- NICE guideline NG49 recommends lifestyle modification as first-line NAFLD management, targeting 7–10% body weight loss, dietary changes, and increased physical activity.
- Non-invasive fibrosis scores (FIB-4, NAFLD fibrosis score) and tests like FibroScan are used to assess liver disease severity and guide specialist referral decisions.
Table of Contents
Am I eligible for weight loss injections?
Find out whether you might be eligible!
Answer a few quick questions to see whether you may be suitable for prescription weight loss injections (like Wegovy® or Mounjaro®).
- No commitment — just a quick suitability check
- Takes about 1 minute to complete
Does Fatty Acid Synthesis Occur in the Liver?
Yes, fatty acid synthesis does occur in the liver, and it represents one of the organ's fundamental metabolic functions. The liver is a major site of de novo lipogenesis in humans, a biochemical process whereby excess dietary carbohydrates are converted into fatty acids for energy storage. This metabolic pathway is particularly active during periods of caloric surplus, when energy intake exceeds immediate metabolic demands.
Whilst adipose tissue also possesses the enzymatic machinery for fatty acid synthesis, the liver's contribution to de novo lipogenesis becomes especially significant with high intakes of refined carbohydrates and free sugars, particularly fructose. In typical mixed diets, de novo lipogenesis usually contributes modestly to circulating triglycerides, but this increases substantially with high free sugar intake and in states of insulin resistance. The hepatocytes—the functional cells of the liver—contain all the necessary enzymes and cofactors to synthesise saturated and monounsaturated fatty acids from acetyl-CoA, the central metabolic intermediate derived primarily from glucose and other substrates.
The capacity for hepatic fatty acid synthesis serves several physiological purposes. It enables the body to store excess energy efficiently, provides substrates for the synthesis of complex lipids such as phospholipids and cholesterol, and supports the production of very-low-density lipoproteins (VLDL) for lipid transport throughout the circulation. Under normal circumstances, this process is tightly regulated by hormonal signals, nutritional status, and cellular energy requirements, maintaining metabolic homeostasis and preventing pathological fat accumulation within the liver itself.
How the Liver Produces Fatty Acids
Hepatic fatty acid synthesis is a complex, multi-step biochemical process that occurs primarily in the cytoplasm of hepatocytes. The pathway begins with acetyl-CoA, which is generated in the mitochondria from the breakdown of glucose via glycolysis and the citric acid cycle. Since acetyl-CoA cannot directly cross the mitochondrial membrane, it is first converted to citrate, which is then transported into the cytoplasm and cleaved back to acetyl-CoA by the enzyme ATP citrate lyase.
The committed step in fatty acid synthesis is catalysed by acetyl-CoA carboxylase (ACC), which converts acetyl-CoA to malonyl-CoA. This is the rate-limiting step and is subject to extensive regulation. Malonyl-CoA then serves as the two-carbon donor for chain elongation, a process orchestrated by the multi-enzyme complex fatty acid synthase (FAS). Through repeated cycles of condensation, reduction, dehydration, and further reduction, FAS sequentially adds two-carbon units to build palmitate, a 16-carbon saturated fatty acid (16:0).
Once palmitate is synthesised, it can undergo further modifications. Elongases extend the carbon chain to produce longer fatty acids such as stearate (18 carbons), whilst desaturases, particularly stearoyl-CoA desaturase-1 (SCD-1), introduce double bonds to generate monounsaturated fatty acids like oleate. These newly synthesised fatty acids are then esterified with glycerol to form triglycerides, which are packaged into VLDL particles for secretion into the bloodstream or stored temporarily within hepatocytes. The entire process requires substantial amounts of NADPH, supplied primarily by the pentose phosphate pathway and malic enzyme, as well as ATP for energy.
Factors That Influence Hepatic Fatty Acid Synthesis
Hepatic fatty acid synthesis is dynamically regulated by nutritional, hormonal, and genetic factors that respond to the body's metabolic state. Dietary composition plays a pivotal role: high carbohydrate intake, particularly refined sugars and fructose, strongly stimulates de novo lipogenesis. Fructose is especially lipogenic because it bypasses key regulatory steps in glycolysis and provides abundant substrates for fatty acid synthesis. The UK Scientific Advisory Committee on Nutrition (SACN) has highlighted the link between high free sugar intake and increased intrahepatic fat accumulation, recommending that free sugars should not exceed 5% of total energy intake. The effect of dietary fat on hepatic lipogenesis is complex and context-dependent; in some circumstances, high fat intake may reduce carbohydrate-driven lipogenesis through substrate competition and feedback mechanisms, though this varies with overall dietary pattern and metabolic state.
Hormonal regulation is equally critical. Insulin, released in response to feeding and elevated blood glucose, is the primary anabolic hormone that activates fatty acid synthesis. It upregulates the expression of key lipogenic enzymes including ACC, FAS, and SCD-1 through activation of transcription factors such as sterol regulatory element-binding protein-1c (SREBP-1c) and carbohydrate response element-binding protein (ChREBP). In contrast, glucagon and adrenaline, released during fasting or stress, inhibit lipogenesis and promote fatty acid oxidation instead.
Genetic and epigenetic factors also influence individual variation in hepatic lipogenesis. Polymorphisms in genes encoding lipogenic enzymes or transcription factors can affect the efficiency of fatty acid synthesis. Additionally, emerging research suggests that the gut microbiome may modulate hepatic lipid metabolism, with certain bacterial metabolites potentially influencing lipogenesis, though this remains an active area of investigation.
Other factors include physical activity, which reduces hepatic lipogenesis by improving insulin sensitivity and altering substrate availability, and circadian rhythms, as lipogenic enzyme expression appears to follow diurnal patterns aligned with feeding cycles, though the clinical significance of this is still being explored. Chronic alcohol consumption also significantly impacts hepatic fatty acid metabolism, promoting both increased synthesis and impaired fatty acid oxidation. The UK Chief Medical Officers recommend not regularly drinking more than 14 units of alcohol per week to reduce health risks, including liver disease.
Clinical Significance of Liver Fatty Acid Production
Understanding hepatic fatty acid synthesis has important clinical implications, particularly in the context of metabolic health and cardiovascular disease. The liver's capacity to convert excess carbohydrates into fatty acids represents a double-edged sword: whilst it provides metabolic flexibility during periods of variable nutrient availability, dysregulated lipogenesis contributes to several prevalent conditions.
Non-alcoholic fatty liver disease (NAFLD), also increasingly referred to as metabolic dysfunction-associated steatotic liver disease (MASLD) in updated nomenclature, is common in the UK and represents the hepatic manifestation of metabolic syndrome. Excessive de novo lipogenesis, driven by insulin resistance, high-carbohydrate diets (particularly high free sugar intake), and genetic predisposition, leads to hepatic steatosis (fat accumulation). When accompanied by inflammation and hepatocyte injury, this progresses to non-alcoholic steatohepatitis (NASH), which can ultimately result in cirrhosis and hepatocellular carcinoma. NICE guideline NG49 emphasises lifestyle modification as first-line management, focusing on weight reduction (target 7–10% body weight loss), dietary changes (reducing refined carbohydrates, free sugars, and saturated fats), and increased physical activity.
Hepatic lipogenesis also influences cardiovascular risk. The liver packages newly synthesised fatty acids into VLDL particles, which are secreted into the circulation and subsequently converted to low-density lipoprotein (LDL) cholesterol. Elevated hepatic lipogenesis therefore contributes to atherogenic dyslipidaemia, characterised by high triglycerides, increased small dense LDL particles, and reduced high-density lipoprotein (HDL) cholesterol.
From a therapeutic perspective, several medications target aspects of hepatic lipid metabolism. Statins primarily inhibit cholesterol synthesis and also have modest effects on triglyceride levels. Importantly, statins are recommended and safe for cardiovascular risk reduction in people with NAFLD and should not be withheld due to mild, stable liver enzyme abnormalities, in line with NICE guidance on lipid management (NG238). Emerging therapies specifically targeting ACC or FAS are under investigation for NAFLD but are not currently licensed in the UK. Understanding individual variation in hepatic lipogenesis may eventually enable personalised dietary and pharmacological interventions to optimise metabolic health and reduce disease risk.
When Liver Fat Synthesis Becomes Problematic
Whilst physiological fatty acid synthesis is essential for normal metabolism, pathological upregulation leads to hepatic steatosis and its associated complications. Non-alcoholic fatty liver disease (NAFLD) exists on a spectrum from simple steatosis to NASH, fibrosis, and cirrhosis. Key risk factors include obesity, type 2 diabetes, insulin resistance, dyslipidaemia, and metabolic syndrome. Certain medications, including corticosteroids, tamoxifen, and some antiretroviral agents, can also promote hepatic fat accumulation. If you are taking any of these medicines, do not stop them without medical advice; discuss any concerns about side effects with your doctor or pharmacist.
Patients with early NAFLD are typically asymptomatic, with the condition often detected incidentally through abnormal liver function tests or imaging performed for other reasons. It is important to note that liver blood tests (ALT, AST, GGT) can be normal even when significant liver fat or fibrosis is present, so normal results do not exclude NAFLD. As the disease progresses, individuals may experience fatigue, right upper quadrant discomfort, or hepatomegaly. Advanced fibrosis and cirrhosis can present with complications including portal hypertension, ascites, variceal bleeding, and hepatic encephalopathy.
When to seek medical attention: There is no general population screening programme for NAFLD in the UK. However, NICE and British Society of Gastroenterology guidance recommend testing in at-risk groups, particularly people with type 2 diabetes, obesity, or metabolic syndrome. Persistently elevated liver enzymes (ALT, AST, GGT) warrant investigation. Anyone experiencing unexplained fatigue, abdominal swelling, jaundice, or other signs of liver dysfunction should seek prompt medical assessment.
NICE NG49 recommends a stepwise approach to investigation. Initial assessment uses non-invasive fibrosis scores such as the FIB-4 index or NAFLD fibrosis score to stratify risk. If these indicate indeterminate or high risk of advanced fibrosis, a second-line test such as the enhanced liver fibrosis (ELF) test may be used. Liver ultrasound can detect steatosis. Transient elastography (FibroScan) measures liver stiffness to assess fibrosis; where available, the controlled attenuation parameter (CAP) can also quantify steatosis. Referral to hepatology is recommended based on fibrosis risk thresholds defined in NICE NG49. Liver biopsy remains the gold standard for definitive diagnosis but is reserved for cases where non-invasive tests are inconclusive or when NASH with significant fibrosis is suspected.
Management focuses on addressing underlying metabolic dysfunction through weight loss (target 7–10% body weight reduction), dietary modification (reducing refined carbohydrates, free sugars, and saturated fats), regular physical activity, and optimising glycaemic and lipid control. Statins should be used as indicated for cardiovascular risk reduction and are safe in NAFLD. There are currently no licensed pharmacological treatments specifically for NAFLD in the UK, though in specialist care, off-label use of pioglitazone or vitamin E may be considered for selected adults with biopsy-proven NASH after careful risk–benefit discussion, as outlined in NICE NG49. Patients with cirrhosis require specialist hepatology input and surveillance for complications including hepatocellular carcinoma.
If you experience side effects from any medicine, you can report them via the MHRA Yellow Card scheme at www.mhra.gov.uk/yellowcard or by searching for 'Yellow Card' in the Google Play or Apple App Store.
Frequently Asked Questions
Why does the liver make fatty acids instead of just storing glucose?
The liver synthesises fatty acids because fat is a far more efficient energy storage form than glucose or glycogen. Fatty acids provide more than twice the energy per gram compared to carbohydrates, and the body's glycogen storage capacity is limited to approximately 500 grams, whereas fat storage is virtually unlimited, allowing the liver to convert excess dietary carbohydrates into a compact, long-term energy reserve.
Can eating too much sugar cause my liver to produce excess fat?
Yes, high intake of refined sugars and particularly fructose strongly stimulates hepatic fatty acid synthesis and can lead to fat accumulation in the liver. The UK Scientific Advisory Committee on Nutrition recommends limiting free sugars to no more than 5% of total energy intake to reduce the risk of non-alcoholic fatty liver disease and other metabolic complications.
What happens to the fatty acids after the liver makes them?
After synthesis, fatty acids are esterified with glycerol to form triglycerides, which are then packaged into very-low-density lipoprotein (VLDL) particles and secreted into the bloodstream for transport to other tissues. Some triglycerides may be temporarily stored within hepatocytes, but excessive accumulation leads to hepatic steatosis and contributes to cardiovascular risk through elevated circulating triglycerides and atherogenic lipoproteins.
How is fatty acid synthesis in the liver different from fat storage in adipose tissue?
Whilst both the liver and adipose tissue can synthesise fatty acids, the liver is the primary site of de novo lipogenesis in humans, especially with high carbohydrate intake, and packages newly made fat into VLDL for circulation. Adipose tissue primarily stores fatty acids delivered from the bloodstream as triglycerides for long-term energy reserves, though it can also perform some synthesis under certain dietary conditions.
Will taking statins interfere with my liver's ability to make fatty acids?
Statins primarily inhibit cholesterol synthesis rather than fatty acid synthesis, so they do not directly block the liver's production of fatty acids. They are safe and recommended for cardiovascular risk reduction in people with non-alcoholic fatty liver disease and should not be withheld due to mild, stable liver enzyme abnormalities, in line with NICE guidance on lipid management.
How do I know if my liver is making too much fat?
Excessive hepatic fatty acid synthesis typically manifests as non-alcoholic fatty liver disease, often detected through abnormal liver function tests, ultrasound, or FibroScan showing steatosis or fibrosis. However, liver blood tests can be normal even with significant fat accumulation, so if you have risk factors such as type 2 diabetes, obesity, or metabolic syndrome, discuss screening with your GP, as NICE recommends targeted testing in at-risk groups.
The health-related content published on this site is based on credible scientific sources and is periodically reviewed to ensure accuracy and relevance. Although we aim to reflect the most current medical knowledge, the material is meant for general education and awareness only.
The information on this site is not a substitute for professional medical advice. For any health concerns, please speak with a qualified medical professional. By using this information, you acknowledge responsibility for any decisions made and understand we are not liable for any consequences that may result.
Heading 1
Heading 2
Heading 3
Heading 4
Heading 5
Heading 6
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat. Duis aute irure dolor in reprehenderit in voluptate velit esse cillum dolore eu fugiat nulla pariatur.
Block quote
Ordered list
- Item 1
- Item 2
- Item 3
Unordered list
- Item A
- Item B
- Item C
Bold text
Emphasis
Superscript
Subscript
